Successful treatment of life-threatening generalized infantile myofibromatosis using low-dose chemotherapy.

Abstract

Infantile myofibromatosis is the most common fibrous tumor of infancy. The generalized form of the disease is associated with a high rate of early mortality, especially if visceral structures are involved. Various therapeutic strategies have been used in these patients, including high-dose chemotherapy, with the risk of therapy-related toxicity. The authors present two cases of generalized infantile myofibromatosis, with life-threatening visceral and nonvisceral involvement, in which the patients were cured with a combination of low-dose chemotherapy and intensive care. The authors propose a prospective international trial using a safe low-dose chemotherapy protocol to test the efficacy of this treatment strategy.

• Authors: Minal M Gandhi, Paul C Nathan, Sheila Weitzman, Gill A Levitt
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 25 Issue 9 Pg. 750-4 (Sep 2003) ISSN: 1077-4114 [Print] United States
• PMID: 12972815 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Dactinomycin
• Vincristine
• Vinblastine
• Prednisolone
• Methotrexate

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Combined Modality Therapy
• Critical Care
• Dactinomycin (administration & dosage)
• Female
• Humans
• Infant, Newborn
• Male
• Methotrexate (administration & dosage)
• Muscle Neoplasms (congenital, drug therapy)
• Myofibromatosis (congenital, drug therapy)
• Osteolysis
• Prednisolone (administration & dosage)
• Remission Induction
• Respiration, Artificial
• Skin Neoplasms (congenital, drug therapy)
• Soft Tissue Neoplasms (congenital, drug therapy)
• Vinblastine (administration & dosage)
• Vincristine (administration & dosage)